1205-58-9

Basic information

• Product Name: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID
• Synonyms: p-Toluicacid, a-acetamido- (6CI,7CI,8CI);4-[(Acetylamino)methyl]benzoic acid; N-Acetyl-4-aminomethylbenzoic acid; N-Acetyl-p-aminomethylbenzoicacid; p-(Acetamidomethyl)benzoic acid
• CAS NO: 1205-58-9
• Molecular Formula: C₁₀H₁₁NO₃
• Molecular Weight: 193.2
• Mol File: 1205-58-9.mol
• Article Data: 8

Chemical Properties

• Melting Point: 194-196 °C
• Boiling Point: 469.5°Cat760mmHg
• Flash Point: 237.7°C
• Appearance: /
• Density: 1.228g/cm³
• Vapor Pressure: 1.17E-08mmHg at 25°C
• Storage Temp.: 2-8°C
• PKA: 4.25±0.10(Predicted)
• CAS DataBase Reference: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(1205-58-9)
• EPA Substance Registry System: 4-[(ACETYLAMINO)METHYL]BENZOIC ACID(1205-58-9)

Safety Data

• Hazardous Substances Data: 1205-58-9(Hazardous Substances Data)

Usage

General Description

4-[(Acetylamino)methyl]benzoic acid is a chemical compound with the molecular formula C10H11NO3. Also known as N-[(4-acetylamino)phenyl]methanesulfonamide, it is an intermediate for the synthesis of a wide range of pharmaceuticals and other organic compounds. It is commonly used as an active ingredient in over-the-counter pain relievers and fever reducers. 4-[(Acetylamino)methyl]benzoic acid also has potential applications in the production of anti-inflammatory drugs and other medications targeting specific biological pathways. As a versatile building block, it is often used in the chemical industry for the creation of new molecules with therapeutic properties.

InChI:InChI=1/C10H17NO3/c1-7(12)11-6-8-2-4-9(5-3-8)10(13)14/h8-9H,2-6H2,1H3,(H,11,12)(H,13,14)/p-1

Upstream product

• 56-91-7 p-aminomethylbenzoic acid 
• 64-19-7 acetic acid 
• 108-24-7 acetic anhydride 

Downstream Products

• 20686-40-2 4-(acetylamino-methyl)-benzoic acid methyl ester 
• 223511-24-8 N-(4-((4-(4-methoxyphenyl)piperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223512-42-3 N-(4-((4-phenylpiperazin-1-yl)methyl)phenylmethyl)acetamide 
• 223512-41-2 N-(4-chloromethyl-benzyl)-acetamide 
• 136869-07-3 N-acetyl(4-hydroxymethyl)benzylamine 

Relevant articles and documents

Harnessing the anti-nociceptive potential of nk2 and nk3 ligands in the design of new multifunctional μ/δ-opioid agonist–neurokinin antagonist peptidomimetics

Opioid agonists are well-established analgesics, widely prescribed for acute but also chronic pain. However, their efficiency comes with the price of drastically impacting side effects that are inherently linked to their prolonged use. To answer these liabilities, designed multiple ligands (DMLs) offer a promising strategy by co-targeting opioid and non-opioid signaling pathways involved in nociception. Despite being intimately linked to the Substance P (SP)/neurokinin 1 (NK1) system, which is broadly examined for pain treatment, the neurokinin receptors NK2 and NK3 have so far been neglected in such DMLs. Herein, a series of newly designed opioid agonist-NK2 or-NK3 antagonists is reported. A selection of reported peptidic, pseudo-peptidic, and non-peptide neurokinin NK2 and NK3 ligands were covalently linked to the peptidic μ-opioid selective pharma-cophore Dmt-DALDA (H-Dmt-D-Arg-Phe-Lys-NH2 ) and the dual μ/δ opioid agonist H-Dmt-D-Arg-Aba-βAla-NH2 (KGOP01). Opioid binding assays unequivocally demonstrated that only hybrids SBL-OPNK-5, SBL-OPNK-7 and SBL-OPNK-9, bearing the KGOP01 scaffold, conserved nanomo-lar range μ-opioid receptor (MOR) affinity, and slightly reduced affinity for the δ-opioid receptor (DOR). Moreover, NK binding experiments proved that compounds SBL-OPNK-5, SBL-OPNK-7, and SBL-OPNK-9 exhibited (sub)nanomolar binding affinity for NK2 and NK3, opening promising opportunities for the design of next-generation opioid hybrids.

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Novel phenylpiperazine derivatives as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity

Phenylpiperazine derivatives were synthesized as dual cytokine regulators with TNF-α suppressing and IL-10 augmenting activity. Lead optimization led to compound 5k having the potent regulatory activity and demonstrating remarkable protective effects against the lethal challenge of LPS in mice, suggesting that 5k would be a promising drug candidate for the treatment of TNF-α associated diseases including septic shock. (C) 2000 Elsevier Science Ltd. All rights reserved.